Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease.

ABSTRACT:

Introduction

Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period.

Case presentation

We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine.

Conclusion

The current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.

SUBMITTER: Fan QY 

PROVIDER: S-EPMC9561359 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature